What Changed

IQVIA launched Predictive Clinical Development, a suite covering site selection and study design, an automated start up path it calls Push Button Start-Up, and real time data cleaning aimed at shortening the gap to database lock.

Our read

Each of the three targets a different well known delay, and the one worth interrogating is real time data cleaning, because database lock timelines are usually held up by query resolution rather than by query generation. Sponsors evaluating this should ask which of the three has a measured effect on an actual study rather than a modelled one.

BrainCheck added BrainCheck Screen, a pre screening tool that identifies which patients need fuller cognitive testing. The vendor reports validation on a 99 patient dataset showing 92 percent sensitivity and 74 percent specificity for detecting cognitive impairment.

Our read

A stated population and both operating characteristics is more than most vendors in this index publish, and it is enough to reason about. Sensitivity of 92 percent with specificity of 74 percent is the right shape for a pre screen, since the job is to avoid missing people and to accept that a quarter of those flagged will test normal. The dataset is small at 99 patients, so the number to ask about is performance in a primary care population rather than a validation cohort.

Lumea integrated TreatmentGPS's Alpine Path into its digital pathology platform, embedding treatment guidance into the pathology report itself. For prostate and bladder biopsies the report now carries NCCN based risk stratification, ancillary testing recommendations and a plain language summary written for the patient.

Our read

This moves the pathology report from a finding to a recommendation, which is a genuine widening of what a pathologist is publishing and worth a governance conversation before it is switched on. The plain language summary is the quietly significant part, since it means the report is now written for two audiences with different tolerances for uncertainty.

CMS approved a New Technology Add-on Payment for Bayesian Health's FDA cleared continuous AI sepsis monitor, creating Medicare payment support for health systems running the platform.

Our read

This is the rarest event in this index, which is an AI tool acquiring a reimbursement pathway rather than only a clearance. Clearance establishes that a product may be used and says nothing about who pays for it, and the absence of a payment mechanism is the reason most cleared clinical AI stalls after the pilot. An NTAP moves the conversation from the innovation budget to the operating one.

Clearwave connected its Scheduling Agent to Reserve with Google, which puts a Book Online button on a practice's Google Business Profile. Patients can book from Google Search and Maps without being handed off to a separate site.

Our read

Patient acquisition for most practices happens on a search results page, and every redirect between that page and a confirmed appointment loses people. Removing the handoff is a small change with a measurable outcome, and it is measurable, which makes it worth asking the vendor for booking completion rates before and after.

bioAffinity extended CyPath Lung from early detection into surveillance of lung cancer survivors. The noninvasive sputum test is now positioned to complement CT imaging when monitoring for recurrence and when evaluating new or changing pulmonary nodules in patients who have completed curative intent treatment.

Our read

Surveillance is a larger and more repetitive population than initial screening, so this is a meaningful widening of where the test can sit in a pathway. The specific job is risk stratification when imaging is equivocal, which is the moment a pulmonologist currently has to choose between watchful waiting and an invasive procedure on incomplete information.

LeanTaaS acquired Aidin and will connect its care transition workflows to iQueue for Inpatient Flow. Aidin's post acute placement workflow now sits downstream of LeanTaaS's discharge readiness intelligence rather than alongside it.

Our read

Anyone currently evaluating Aidin is now evaluating LeanTaaS, with the contract, roadmap and support relationship that implies. The combined product is a bet that discharge delays are a capacity problem and a placement problem at the same time, which is true in most hospitals and is why the two have historically been bought separately and blamed on each other.

Xsolis launched GenAI Peer-to-Peer Clinical Synopsis as an add on inside Dragonfly Advise. It reads longitudinal EMR data including labs, vitals and nursing notes, and generates a structured synopsis highlighting severity indicators and medical necessity rationale ahead of a peer to peer denial review.

Our read

The vendor puts the manual version of this task at 15 to 20 minutes of chart reconstruction inside a 24 to 72 hour regulatory window, which is a specific enough claim to test against a physician advisor's own calendar. The risk to check in evaluation is what the synopsis omits, since a medical necessity argument built from a summary is only as good as the exclusions nobody sees.

LeanTaaS

Sep 1, 2026

HighVerified

LeanTaaS acquired Aidin and is folding discharge readiness intelligence and post acute placement into iQueue for Inpatient Flow, extending the platform from admission through transition out.

Our read

LeanTaaS has sold capacity optimisation inside the hospital walls for a decade, and the constraint it kept hitting was a bed that cannot be freed because a post acute placement has not been arranged. Buying the placement workflow rather than integrating with one is a statement about where it thinks the remaining length of stay savings are.

Insilico Medicine

Sep 1, 2026

HighVerified

Insilico released a set of small language models trained as scientific specialists for chemistry and biology through its MMAI Gym for Science framework. The set covers chemical synthesis, ADMET prediction and potency prediction across GPCR and kinase panels, and includes a single step retrosynthesis model built on Liquid AI's 2.6 billion parameter architecture.

Our read

Naming the base architecture and the parameter count is unusual in this category and is the reason this is graded on model transparency rather than capability alone. For discovery teams the practical read is that these are narrow specialists rather than a general assistant, which is the right shape for ADMET and potency work where a confident wrong answer is expensive.

Abridge

Aug 28, 2026

HighVerified

Abridge shipped its August 2026 release with four additions that push the product upstream of the encounter it was built to document. Pre Visit Summaries synthesize a patient's history, active problems and recent changes before the visit, with every detail linked back to its source in the chart. Pre Admission Summaries do the equivalent for inpatient handoff, aggregating the emergency department course, labs, vitals, imaging and prior documentation into one view at the start of an admission. The release also adds transparent level of service recommendations for coding, and lets clinicians claim AMA PRA Category 1 CME credit for reviewing eligible topics at the point of care.

Our read

An ambient scribe that also prepares the clinician before the encounter is competing for a different budget line than one that only writes the note, and the source linking is what makes the summary usable in a setting where an unverifiable synthesis is a liability. The coding recommendation being described as transparent matters to compliance teams, since level of service suggestions that cannot be explained are exactly what draws payer scrutiny. The CME element is the genuine novelty and it is worth watching, because attaching accredited education to routine chart review changes what the tool is worth to a clinician personally rather than only to the organization.

CarePilot

Aug 28, 2026

MediumVerified

CarePilot published release notes covering organization wide note attestation settings, automated questionnaire scoring during intake, and the ability to record visit length. The release adds preventive screening and ENT codes to billing suggestions, expands text macro support, and tightens the account lockout policy to five failed attempts. It is a routine release, but a named and described one, which is the bar this log applies to release notes.

Our read

Organization wide attestation settings are the difference between each clinician deciding how a note is signed and a practice enforcing one standard, which is what an auditor looks for. Automated questionnaire scoring at intake removes a manual transcription step where errors quietly propagate into the clinical record. The lockout policy change is small but is the kind of control that appears on security questionnaires, and its presence in a public release note is itself a useful transparency signal.

Caris Life Sciences

Aug 27, 2026

HighVerified

Caris Life Sciences published a study in npj Precision Oncology reporting that its AI guided therapy selection predicts longer survival in pancreatic cancer patients. Pancreatic cancer is a deliberately hard test case, with short survival and few targetable alterations, so a survival signal there is a stronger claim than the same signal in a more tractable tumor type. The work validates Caris AI Insights specifically rather than the molecular profiling platform in general.

Our read

This is peer reviewed and reports survival rather than a surrogate such as concordance with a tumor board or rate of actionable findings, which places it at the top of the evidence hierarchy in this category. Oncology services can cite it directly when justifying AI guided profiling to a formulary or utilization committee. The caveat buyers should carry is that predicting longer survival in a retrospective cohort is not the same as demonstrating that following the recommendation caused it, and the study design determines which of those two claims is supported.

OmniMD

Aug 27, 2026

HighPartially Verified

OmniMD launched an AI Revenue Intelligence product with remote patient monitoring built in rather than bolted alongside. The release covers AI assisted patient onboarding, vital sign streaming, AI generated clinician summaries, and an audit grade billing workflow that creates the note natively in the EHR and hands it off. Pairing monitoring with the billing trail directly is the design decision worth noting, since RPM programs usually fail on documentation rather than on data capture.

Our read

RPM reimbursement depends on evidencing monitoring time and clinical review, and practices routinely lose billable activity because the documentation lives somewhere the biller cannot reach. Unifying capture, summary and billing addresses the real leak. Buyers should verify what audit grade means concretely in this context, specifically whether the system records the reviewing clinician, the time spent and the interaction in a form that survives a payer audit.

Waystar

Aug 26, 2026

HighVerified

Waystar launched agentic AI capabilities inside its AltitudeAI platform, moving from software that scores and routes work to agents that carry the work out. The release covers claim resolution, conversational performance intelligence, and agentic clinical documentation that reads the full medical record and pre populates correction requests with the supporting clinical context already attached. Waystar reports roughly a 40 percent reduction in manual correction workload in early deployments.

Our read

Revenue cycle vendors have been describing their products as AI for years while shipping prioritization tools, so a claim about agents completing corrections rather than queueing them is a genuine category shift if it holds. The 40 percent figure is the number to test, specifically what baseline it is measured against and whether the corrections the agent produces are accepted at the same rate as human authored ones. The oversight question also matters, since an agent that assembles a correction request is operating on the documentation that supports a claim.

Luma Health

Aug 26, 2026

HighVerified

Luma Health shipped its Summer 2026 release, extending its Operational AI from pre visit preparation into what happens once the patient is physically in the clinic. Patients can now self check in by kiosk or QR code, an enhanced Queue Manager routes arrivals to the appropriate queue automatically, and new financial administration tooling supports facility managed card readers and transaction reporting. The through line is closing the gap between the digital front door and the front desk.

Our read

Most patient access platforms stop at the appointment and hand off to a separate check in system, which is exactly where the operational data trail breaks. Unifying arrival, queueing and payment under one system gives front desk staff live visibility instead of reconstructing the morning afterwards. Buyers should confirm how the card reader support interacts with their existing merchant processing relationship, since payment infrastructure is the part of this that is hardest to swap later.

Nabla

Aug 25, 2026

MediumVerified

Nabla released version 2026-08-25 of its Core API. An optional specialty field was added to user management and note generation on the Server API, and an encounter date field was added to note generation on both the User and Server APIs, so a caller can now tell Nabla what kind of encounter it is transcribing instead of leaving the model to infer it. The release also introduces an audio chunk acknowledgement protocol and enforces strict endpoint path prefixes, which is a breaking change for anyone relying on loose paths.

Our read

Passing specialty and encounter date at request time is the difference between a generic note and one shaped to the documentation conventions of the service producing it, which is usually where scribe output quality is won or lost. The audio acknowledgement protocol addresses silent data loss in streaming capture, a failure that is difficult to detect after the fact. Anyone with an existing Nabla integration should read the path prefix enforcement as required migration work rather than an optional improvement.

Suki

Aug 25, 2026

HighPartially Verified

Suki launched Suki Dictation, a standalone clinical dictation product built natively inside Epic and Meditech rather than delivered as a separate application alongside them. Clinicians can generate notes, edit by voice command and place the result directly into the EHR. The strategic point is that it is sold separately from Suki's ambient scribe, so an organization can buy dictation without committing to full ambient documentation.

Our read

Plenty of health systems want to replace legacy dictation without taking on the change management and clinician consent work that an ambient scribe rollout requires, and until now that meant choosing between an old product and a bigger project than they wanted. Native Epic and Meditech embedding also removes the second window that made previous generation dictation tools unpopular. For buyers this is most interesting as a lower commitment entry point that leaves the ambient upgrade available later.

Eleos Health

Aug 25, 2026

MediumVerified

Eleos Health shipped version 10.0.17. The release extends the Eleos sidebar to additional URLs and adds the ability to populate dropdown fields, meaning the assistant can now write into structured EHR fields rather than only free text. Note type visibility was tightened so notes surface only to the providers they are relevant to, audio capture resources in the web app were optimized, and integration defects were fixed in MyEvolv pop up screens and PCE sidebar reloading.

Our read

Behavioral health documentation lives in structured assessment fields as much as in narrative, so writing into dropdowns is what separates a scribe that drafts a note from one that completes a record. The visibility change is a quiet but real governance improvement, since over broad note visibility inside a behavioral health EHR is a genuine confidentiality exposure. The named fixes to MyEvolv and PCE are also a useful signal of which EHRs Eleos is actively maintaining against.

Aidoc

Aug 25, 2026

MediumPartially Verified

Mercy and Aidoc released a white paper, commissioned by AVIA, reporting on five months of AI deployment across the Mercy health system. The review documents more than 50,000 new clinical findings surfaced in that window and tracks the associated changes in speed of diagnosis and time to treatment. The scale is the notable part: this is a multi hospital deployment reporting aggregate output rather than a single site pilot.

Our read

A five month figure from a named health system gives buyers something to model against, which vendor accuracy claims do not. The number to interrogate is what counts as a new clinical finding, since that definition determines whether 50,000 represents meaningful catches or a high volume of flags a radiologist would have reached anyway. AVIA commissioning the work makes it more independent than a vendor case study and less independent than peer review, which is roughly where its evidentiary weight should sit.

Stratipath

Aug 25, 2026

HighVerified

Stratipath Breast received CE marking under the European Union In Vitro Diagnostic Regulation, EU 2017/746. IVDR is a substantially higher bar than the IVD Directive it replaced, requiring clinical evidence, demonstrated analytical validity and an ongoing post market surveillance commitment rather than largely self declared conformity. For an AI based prognostic tool this is one of the more demanding routes to European market access currently available.

Our read

European pathology labs and oncology departments can deploy the tool clinically rather than for research use only, which is the practical distinction that determines whether a result can inform a treatment decision. The post market surveillance obligation is worth weight in a vendor comparison, because it commits Stratipath to monitoring real world performance rather than resting on the validation study. Buyers comparing AI pathology vendors across regions should note that IVDR certification and FDA clearance are not interchangeable and cover different claims.

Hyro

Aug 25, 2026

MediumVerified

Hyro published a breakdown of the architecture behind its patient scheduling agent, disclosing that it orchestrates seven distinct smaller models rather than driving the workflow from one large language model. Individual models are dedicated to isolated jobs such as extracting date and time constraints from what the patient said, querying slot availability, and answering general questions. The design deliberately trades the flexibility of a single large prompt for narrower components whose failures are easier to localize.

Our read

Architecture disclosure at this level is rare in this category and is directly useful, because it tells a buyer where a scheduling error would come from and whether it can be fixed without retraining the whole system. Task isolation also reduces the failure mode where a long instruction set produces contradictory behavior under pressure. Treat the disclosure itself as the change worth logging, since a vendor willing to describe its model topology is easier to evaluate than one that will only describe outcomes.

Commure

Aug 25, 2026

MediumVerified

Commure released version 2026.3.1 of its Pro iOS app. The headline addition is a widget that starts or resumes an AI Scribe session straight from the iOS Home Screen or Lock Screen, removing the app open and navigate steps before recording begins. The release also promotes AI Studio into the main tab bar for users with AI Scribe enabled, and opens the Scribe panel automatically when a new note is created.

Our read

Ambient scribe adoption is decided by friction at the start of the encounter, since a clinician who has to unlock, find and open an app before a patient interaction will often simply not bother. Moving session start to the lock screen is a small change with a disproportionate effect on the percentage of eligible encounters that actually get captured. Health systems tracking scribe utilization rather than scribe accuracy should treat this as the more consequential release of the two.

Tempus

Aug 24, 2026

HighVerified

Tempus received FDA 510(k) clearance for Tempus ECG PH, software that reads a standard 12 lead electrocardiogram and identifies signs associated with pulmonary hypertension. The device does not require new hardware or a new test, since it runs against ECGs that are already being captured for other reasons. This adds to the cleared cardiovascular algorithm suite Tempus has been assembling, and pulmonary hypertension is a deliberate target because it is characteristically diagnosed late.

Our read

Clearance is the gate that separates a research grade algorithm from something a cardiology service can put into routine practice, and this one runs on data every hospital already has in volume. The deployment question is what happens downstream of a positive flag, because pulmonary hypertension confirmation requires right heart catheterization and a screening tool that raises referral volume without a matching diagnostic pathway creates a bottleneck rather than removing one. Ask for the sensitivity and specificity in the cleared indication and the population it was established in.

FDB (First Databank)

Aug 24, 2026

HighVerified

FDB commercially deployed FDB Script Agent, an AI prescribing tool that converts ambient patient encounter dialogue directly into structured prescriptions. The agent applies FDB's drug terminology codification and clinical validation to what it hears, so the output is a coded medication order rather than free text, and it queues that order for clinician review rather than transmitting it. It launched first on the Tebra platform. This moves ambient listening past documentation and into order entry, which is a materially different risk surface.

Our read

Practices can cut the manual keystrokes of prescription entry, which is one of the slowest steps left in an otherwise automated encounter. The important detail for evaluators is that FDB owns the drug knowledge base underneath the codification, so the structured output inherits an established terminology layer rather than a model's guess at a drug name and dose. Anyone assessing this should focus on the review step: what the clinician sees before signing, and what happens when the agent mishears a dose or a route.

Medallion

Aug 24, 2026

HighVerified

Medallion shipped three platform capabilities at once. An AI provider outreach agent now contacts stalled providers by phone, text and email to chase profile completion, taking over the follow up that credentialing coordinators normally do by hand. Provider profile auto fill populates records from NPPES, CAQH and uploaded documents instead of requiring the provider to retype what already exists in public registries. Self serve webhooks let organizations push enrollment and credentialing status changes into their own systems over API rather than polling for them.

Our read

The bottleneck in credentialing is almost never the review itself, it is waiting on providers to return information, so an agent that does the chasing addresses the actual constraint on time to credential. The webhooks matter more than they sound: polling based integrations are what make downstream systems drift out of sync with credentialing status, and that drift is what produces billing for providers who are not yet enrolled. Buyers should ask how the outreach agent identifies itself to providers and what the escalation path is when it fails to reach someone.

Insilico Medicine

Aug 24, 2026

MediumVerified

Insilico Medicine convened the Open Consortium for Benchmark Quality in AI Driven Drug Discovery, known as O3DC, and published a live catalogue of the benchmarks the field uses to claim performance. The catalogue tracks each benchmark's metrics, maintainers and repository activity, and unusually it documents the known caveats, biases and limitations of each one rather than presenting them as neutral yardsticks. The stated premise is that a benchmark with an undisclosed bias produces model comparisons that look rigorous and are not.

Our read

Pharmaceutical evaluators comparing AI drug discovery platforms are almost always comparing benchmark scores, and this is the first centralized attempt to say which of those benchmarks can carry the weight. It is worth noting that the vendor convening a benchmark integrity consortium is also a vendor whose own models are scored on those benchmarks, so the catalogue is useful and is not disinterested. Read it as a map of where the measurement problems are rather than as an independent audit.

GeneDx

Aug 24, 2026

MediumVerified

GeneDx published results from a study at Seattle Children's supporting hospital wide adoption of rapid genomic sequencing rather than the usual narrow deployment in the NICU or a single specialty service. The study evaluates both clinical and operational impact of running rapid sequencing across a whole pediatric institution, which is the question health systems actually face when deciding how far to extend a genomics program.

Our read

Evidence generated at a named academic pediatric center is a stronger basis for a capital decision than vendor authored case studies, and hospital wide is a meaningfully harder claim than a single unit pilot. Buyers evaluating a genomics program should read the operational half closely, since diagnostic yield is usually the easy part and turnaround time, ordering workflow and counselling capacity are what determine whether the program survives contact with a general ward.

Brainomix

Aug 24, 2026

MediumVerified

A study was published evaluating what happened when Brainomix 360 Stroke was implemented in a high volume stroke system that already used routine perfusion imaging. The finding is that the platform improved the efficiency of the acute stroke pathway even in a setting that was not imaging constrained to begin with. The design matters here, because it is an implementation study in an operating service rather than a retrospective accuracy comparison against a reference standard.

Our read

Most stroke AI evidence measures whether the algorithm agrees with an expert reader, which tells a buyer very little about whether the service gets faster. This one measures the pathway, which is the thing hospital leaders are actually purchasing. The high volume, routine perfusion setting is the harder test case, since those centers have the least headroom for an AI tool to add value, so a positive result there travels further than one from an under resourced site.

Paige

Aug 23, 2026

HighVerified

Paige launched an AI tool that screens 505 genes directly from H and E stained pathology slides, without requiring next generation sequencing as a first step. The model predicts a comprehensive genomic profile from routine morphology alone and flags potential biomarkers for follow up. Rather than replacing sequencing, it is positioned as a triage layer that decides which cases warrant the full molecular workup. Paige is applying the same foundation model approach it built for cancer detection to molecular prediction.

Our read

Pathology labs and oncology practices can screen for hundreds of mutations off slides they already produce, compressing the time between biopsy and a targeted therapy decision. The economic argument is sequencing avoidance: labs run the expensive molecular test on the subset the model flags rather than on everything. Buyers should ask which of the 505 genes have been validated against sequencing ground truth and at what sensitivity, because a screening tool that misses a targetable mutation carries a different risk profile than one that over refers.

Corti

Aug 21, 2026

HighVerified

Corti announced the General Availability of its Guided Generation endpoints for text generation. Concurrently, the Documents Classic endpoint was deprecated, with a final sunset date of January 18, 2027.

Our read

Developers and healthcare organizations using Corti's text generation APIs must migrate to the new Guided Documents endpoint before the January 2027 sunset date to avoid service disruption. The GA status of Guided Generation also signals production readiness for structured clinical note generation.

OpenEvidence

Aug 20, 2026

MediumVerified

OpenEvidence launched Patient Take-Homes, a new feature allowing clinicians to optionally turn AI-generated answers into educational materials for their patients. The feature enables doctors to share specific, curated clinical evidence directly with patients at their discretion.

Our read

This capability extends the platform's utility beyond clinician-facing decision support into patient engagement and education. Buyers can leverage this to improve patient health literacy and streamline the creation of evidence-based post-visit summaries.

mdhub

Aug 20, 2026

HighVerified

mdhub introduced three new platform capabilities: AI Analytics for custom reporting on clinical and financial metrics, an AI Care Coordinator named Laura for patient engagement via the portal, and an automated Chart Audit tool to review documentation against payer requirements.

Our read

Behavioral health clinics can now automate between-visit patient follow-ups to reduce churn, proactively catch documentation gaps before claims are denied, and generate custom operational reports without manual data exports.

Scribble by IKS Health

Aug 19, 2026

HighVerified

IKS Health launched Scribble Select, a new feature within the Scribble Suite that allows clinicians to choose between AI-only documentation, AI with human validation, or fully clinician-reviewed notes for each visit. The feature enables users to adjust the level of support based on specific clinical workflows without switching platforms.

Our read

Buyers can offer their clinicians flexible documentation options within a single platform, accommodating varying preferences for AI autonomy versus human oversight. This flexibility helps tailor the cost and turnaround time to the complexity of individual patient encounters while reducing friction in adoption.

Oracle Health Clinical AI Agent

Aug 19, 2026

HighPartially Verified

Oracle Health expanded its Clinical AI Agent with new capabilities for automated professional fee coding, AI-powered chart review, and clinician-controlled dictation. The update allows the AI to surface relevant clinical context across EHRs, summarize patient information, and transcribe speech in real time directly into any text field.

Our read

Health systems can reduce manual review and rework in revenue cycle workflows by leveraging the new professional fee coding support. Additionally, the chart review and dictation features provide clinicians with more flexible tools to quickly access patient context and complete documentation directly within text fields.

Ambience Healthcare

Aug 19, 2026

HighVerified

Ambience Healthcare introduced 'The Ambience Standard,' a new performance-based commercial model for its AI platform. Under this model, partnership fees are directly tied to the achievement of measurable clinical, operational, and financial outcomes.

Our read

This pricing structure shifts financial risk away from health systems by aligning vendor compensation with actual realized ROI, such as improved coding accuracy and documented time savings. Buyers evaluating Ambience can now structure contracts based on verified performance metrics rather than standard software licensing fees.

GeneDx

Aug 19, 2026

MediumVerified

GeneDx introduced Exome-to-Genome Reflex ordering within Epic Aura and other supported point-to-point EHR integrations. This capability allows providers to automatically trigger a genome test if the initial exome test results are negative or inconclusive.

Our read

This integration streamlines the diagnostic workflow for clinicians using Epic by eliminating the need to manually place secondary orders. It reduces administrative friction and can accelerate the time to a definitive genetic diagnosis for patients.

Owkin

Aug 18, 2026

HighVerified

Owkin received European regulatory approval for two first-in-class AI diagnostic solutions designed for breast cancer and colorectal cancer. The tools leverage multimodal patient data to assist in biomarker screening and outcome prediction.

Our read

European healthcare providers and laboratories can now clinically deploy these validated AI diagnostic tools. This provides pathologists and oncologists with approved decision support for breast and colorectal cancer diagnostics.

Sword Health

Aug 18, 2026

LowVerified

Sword Health published a clinical and economic evidence report on its continuous AI MSK care model, reporting $3,177 in direct savings per member per year, a 3.2x return on investment, and that 54% of members with moderate to severe surgery intent remained surgery-free. The figures are Sword's own analysis and have not been independently verified.

Our read

The report consolidates Sword's ROI and surgical-avoidance claims in one place, but it is a vendor-published evidence summary rather than a peer-reviewed study. Buyers should request the underlying methodology and cohort definitions before using these figures in a business case.

Inspiren

Aug 18, 2026

MediumPartially Verified

Inspiren launched a daily integration with August Health to automatically sync resident census data, including Person IDs, names, and room assignments. The integration automatically updates Inspiren when residents move in, transfer rooms, or discharge.

Our read

Care teams no longer need to maintain separate rosters or perform duplicate data entry across systems, ensuring continuous monitoring without administrative gaps during shift changes or busy move-in days.

4baseCare

Aug 18, 2026

MediumPartially Verified

4baseCare launched TARGT Indiegene V2, a cancer profiling panel expanded to cover 2,206 genes. The updated panel is positioned by the vendor as providing precision oncology insights tailored for diverse and historically underrepresented populations.

Our read

Oncologists and health systems gain access to a significantly expanded genomic panel, which the vendor positions as enabling more precise targeted therapy selection for cancer patients from diverse genetic backgrounds. Reported only in trade press so far; confirm panel specifications at source before relying on them.

Indica Labs

Aug 17, 2026

MediumVerified

Indica Labs announced version 4.3 of its HALO, HALO AI, and HALO Link platforms. The release includes a reworked image copy system in HALO for improved workflow flexibility and new features in HALO AI that the vendor says enable more efficient model testing.

Our read

Pathology labs and researchers can utilize the updated image management system and enhanced model testing tools to streamline their digital pathology operations and validate AI algorithms more effectively.

Abridge

Aug 17, 2026

MediumVerified

Abridge announced the enterprise-wide expansion of its Context-Aware Clinical Intelligence platform, allowing partner health systems to deploy the AI agent to every clinician across their organizations.

Our read

This shift to a system-wide deployment model allows healthcare organizations to scale ambient AI documentation across all specialties and users, standardizing the technology across the enterprise rather than limiting it to early adopters.

Milvue

Aug 14, 2026

MediumVerified

A retrospective single-center study published in Diagnostics externally validated several CE-certified AI systems, including Milvue's TechCare Kids, for automated bone age assessment. The researchers found no significant differences in accuracy between TechCare Kids and the other evaluated AI systems for 90% of the clinically relevant pediatric cohort.

Our read

Prospective buyers evaluating pediatric bone age AI tools can use this independent clinical validation as evidence that Milvue's TechCare Kids performs competitively alongside other commercial solutions. The findings provide clinical reassurance of the model's reliability in standard use cases.

VirtuSense VSTOne

Aug 13, 2026

HighVerified

VirtuSense launched VSTOne Go, a mobile version of its ambient AI fall prevention platform designed specifically for post-acute care and skilled nursing environments. The transportable system uses infrared sensors rather than cameras to continuously monitor residents, predicting unassisted bed or chair exits 30 to 65 seconds in advance while maintaining patient privacy.

Our read

Post-acute and skilled nursing operators can now dynamically deploy predictive fall monitoring across different rooms without the capital expense of permanent hardware installations. Additionally, through an integrated partnership with the CareAgents specialty insurance program, eligible operators adopting the technology can qualify for general liability premium credits to help offset the deployment cost.

Paradigm Health

Aug 13, 2026

HighPartially Verified

Ochsner Health reported outcomes from deploying Paradigm Health's LLM-based clinical trial recruitment platform across its 47 hospitals and 370 health centers. The AI-powered system connects to the EHR to continuously evaluate patient records against eligibility criteria, leading to a 41% increase in screening capacity, a 3.6-fold increase in patients identified for future trial eligibility, and a 75% reduction in manual review effort by clinical research coordinators.

Our read

Real-world operational metrics from a major health system provide robust evidence that this AI platform can significantly scale clinical trial screening volumes without a proportional increase in headcount. The reported 75% drop in manual effort offers a strong return-on-investment case for research administrators seeking to alleviate coordinator burnout and maximize trial enrollment.

Inspiren

Aug 13, 2026

MediumPartially Verified

Inspiren launched a bi-directional integration with Extended Care Professional (ECP), a software platform for assisted living communities. The integration automatically synchronizes resident census changes, room transfers, discharges, and level-of-care updates from ECP directly into Inspiren's AI ecosystem.

Our read

This interoperability eliminates the need for care teams to manually double-enter resident data across platforms. Assisted living operators using both systems can ensure that high-risk resident profiles and safety monitoring contexts remain accurate and up-to-date in real time, reducing administrative burden.

Cedar

Aug 13, 2026

HighPartially Verified

Cedar launched the Kora Platform, evolving its single AI billing agent into an integrated suite of purpose-built AI agents for patient revenue recovery. The platform orchestrates autonomous inbound voice, proactive outbound voice, and two-way text capabilities to handle tasks such as routine billing inquiries, payment processing, and Medicaid enrollment. The agents integrate with existing electronic health records and call center systems, retaining conversation history to carry context across multiple patient interactions.

Our read

Revenue cycle management teams can leverage this multi-channel suite to automate patient financial interactions and contain inbound call volumes. By intelligently determining caller intent and proactively initiating outbound engagement, the platform helps health systems reduce the cost-to-collect for growing self-pay and uninsured patient populations.

Cadence

Aug 13, 2026

HighPartially Verified

Cadence announced that its HypertensionOS software was selected by the FDA as the second participant in the TEMPO for Digital Health Devices Pilot. The prescription Software as a Medical Device (SaMD) utilizes AI-assisted functionality to support clinician-supervised medication initiation and titration for patients with Stage 2 hypertension.

Our read

Participation in the TEMPO pilot enables Cadence to deploy its clinical AI medication management system under FDA enforcement discretion. This allows healthcare buyers to adopt the technology for bounded, automated chronic care workflows while contributing real-world evidence to regulatory frameworks.

Assort Health

Aug 12, 2026

HighVerified

Assort Health announced the general availability of Referrals, a new AI agent designed to automate the inbound referral process end-to-end. The agent extracts data from EHR feeds and faxes, verifies patient eligibility, applies specialty-specific matching criteria to select the appropriate provider, and proactively contacts the patient to schedule the appointment directly in systems like Epic and athenahealth.

Our read

Specialty practices and health systems can deploy this agent to minimize referral leakage and drastically reduce the administrative burden of manual document reviews and outreach. By processing referrals within hours and intelligently identifying the best-fit provider, organizations can accelerate patient access, increase referral-to-appointment conversion rates, and capture previously lost revenue.

OpenEvidence

Aug 12, 2026

MediumVerified

A systematic review published in npj Digital Medicine evaluated 11 studies assessing OpenEvidence's clinical question-answering capabilities. The researchers found that the platform consistently generated evidence-supported responses without fabricating citations, showing peak performance in structured, guideline-based settings. However, the study noted that accuracy varied in complex scenarios and that the system tended to reinforce rather than alter existing clinical decisions.

Our read

This peer-reviewed analysis provides buyers with independent validation of the platform's clinical safety and operational strengths. The findings suggest the tool is highly reliable for guideline-based queries but highlight the need for human oversight in complex cases where it may simply affirm prior clinical judgments.

Techcyte

Aug 12, 2026

HighVerified

A retrospective clinical evaluation study published in the Journal of Clinical Microbiology validated the diagnostic performance of Techcyte's Human Fecal Ova & Parasite Detection Wet Mount Iodine Solution. The artificial intelligence software, used alongside operator review, achieved a 96.62% positive percent agreement and a 93.33% negative percent agreement for detecting protozoan and helminthic infections in stool specimens.

Our read

The published findings provide strong independent validation that the artificial intelligence screening software maintains high diagnostic agreement with traditional microscopy while streamlining laboratory workflows. For microbiology labs, this clinical evidence supports the system's utility as a complementary tool that can reduce manual screening times and help uncover additional parasitic infections.

Ubie

Aug 12, 2026

HighPartially Verified

Ubie's AI-powered patient access tool, Smart Support, has been officially qualified on the Mayo Clinic Platform. The solution evaluates routine patient interactions across phone calls, web chats, and portal messages. It autonomously determines the clinical urgency, appropriate specialty, and correct visit type at intake prior to scheduling.

Our read

Qualification by an independent, reputable body provides health systems with external validation of the algorithm's clinical performance and readiness for real-world workflows. Centralized patient access teams can confidently deploy the tool for high-volume intake routing to reserve staff time for complex cases requiring human judgment.

GeneDx

Aug 11, 2026

MediumPartially Verified

GeneDx launched a new digital offering that enables families of children with global developmental delay, intellectual disability, or epilepsy to initiate exome testing directly from its website. The service connects families with licensed virtual clinicians who review medical histories, order genetic testing, and deliver results without requiring an in-person visit.

Our read

This provides a direct-to-family acquisition channel that circumvents specialty care wait times, which can exceed a year for genetics appointments. Health systems and providers can leverage this virtual-first pathway to complement traditional care and accelerate time-to-diagnosis for pediatric patients.

Corti

Aug 11, 2026

MediumVerified

Corti launched the ICD-10-UK Coding Expert for its Agent Library, a specialized AI model component designed to assign accurate medical codes localized to the United Kingdom standard. The Expert plugs into Corti's Agentic Framework to automate or assist with clinical coding based on patient encounter data.

Our read

UK-based healthcare organizations and NHS trusts can now leverage Corti's AI agent framework to handle local medical coding natively. This reduces administrative overhead and minimizes billing and documentation errors by using the specific ICD-10-UK classification system rather than generalized or US-centric coding models.

mdhub

Aug 11, 2026

HighVerified

mdhub launched a native integration with athenaOne, officially becoming a vetted partner on the athenahealth Marketplace. The integration connects mdhub's AI-powered admissions, clinical documentation, and smart scheduling tools directly to athenaOne workflows.

Our read

Behavioral health practices using athenaOne can now deploy mdhub's AI automation without creating data silos or forcing staff to manage parallel systems. The vetted Marketplace status also ensures the integration meets athenahealth's strict API and data security standards.

Valar Labs

Aug 10, 2026

MediumVerified

Valar Labs and clinical partners published a peer-reviewed study in Urologic Oncology detailing the development and validation of an image-only AI prognostic biomarker for muscle-invasive bladder cancer (MIBC). Built on the company's Computational Histopathology Artificial Intelligence (CHAI) platform, the model extracts features from pre-treatment H&E-stained whole slide images to risk-stratify patients for recurrence-free, cancer-specific, and overall survival.

Our read

Clinical evidence is critical for evaluating AI diagnostics. This validation demonstrates that Valar Labs' underlying CHAI technology can derive meaningful prognostic signals from standard, already-collected pathology slides in MIBC patients, offering oncologists an additional data point for treatment planning without requiring separate molecular tests.

MEDICAL IP

Aug 10, 2026

MediumVerified

A retrospective study published in PLOS ONE validated MEDIP PRO's ability to segment orbital structures on CT imaging to assess Thyroid Eye Disease (TED) activity. The software was used to perform semi-automatic segmentation of extraocular muscles, intraorbital fat, and lacrimal glands. The resulting quantitative metrics successfully differentiated active from inactive TED, demonstrating an area under the curve (AUC) of 0.938 when combined with clinical parameters.

Our read

Published validation provides concrete evidence of the platform's segmentation accuracy and reliability for complex orbital anatomy. Health systems evaluating the solution can point to this study as proof of its capability to extract clinically meaningful, disease-specific biomarkers from routine imaging.

Creyos

Aug 10, 2026

HighPartially Verified

Creyos announced real-world outcomes from its deployment across more than 35 sites at Claremedica, a value-based primary care organization serving over 34,000 Medicare Advantage patients. Over a seven-month period, replacing the paper-based MMSE with Creyos' digital cognitive assessment enabled Claremedica to identify over 90% of new dementia cases at the early or mild stages while reducing average screening times from roughly 12 minutes to six minutes.

Our read

Value-based care buyers evaluate digital screeners on both operational efficiency and diagnostic sensitivity. This named health system outcome validates that the platform can halve administrative screening time without sacrificing clinical rigor, enabling earlier intervention and proactive care planning for Medicare Advantage populations.

Corti

Aug 10, 2026

MediumVerified

Corti added three new pre-built Experts to its Agent Library: the DrugBank Expert for structured medication and interaction queries, the PubMed Expert for retrieving direct research evidence, and the Interviewing Expert for running adaptive clinical questionnaires. These modules operate within the Corti Agentic Framework via the Model Context Protocol (MCP) to provide identifier-grounded intelligence without medical hallucination.

Our read

Healthcare developers can now easily build AI agents that tap directly into authoritative drug databases and peer-reviewed literature. This modular approach accelerates development for complex workflows like medication reconciliation while ensuring agents rely on verifiable, structured data rather than speculative generative models.

Censinet

Aug 6, 2026

MediumVerified

Censinet introduced comprehensive support for the new HHS Cybersecurity Performance Goals (CPGs) within its risk management platform. The update provides built-in capabilities to help healthcare organizations track and accelerate their compliance with the federal cybersecurity guidelines.

Our read

Security and risk teams can now natively assess and map their organization's posture against the HHS CPGs directly within Censinet. This reduces manual compliance tracking and ensures alignment with national healthcare cybersecurity standards.

UpToDate

Aug 6, 2026

MediumVerified

Wolters Kluwer expanded its generative AI solution, UpToDate Expert AI, by integrating comprehensive medication data from UpToDate Lexidrug. This enhancement allows the AI assistant to provide rigorously reviewed drug dosing and medication decision support directly within its conversational interface.

Our read

Healthcare organizations evaluating UpToDate Expert AI can now leverage the tool for complex medication-related queries, which historically account for nearly 30 percent of clinician questions on the platform. This integration streamlines workflows by reducing the need for clinicians to switch between separate drug reference databases and the main AI assistant.

Sully.ai

Aug 6, 2026

HighVerified

Sully.ai released an AI scribe specifically designed for nursing shifts, expanding its capabilities beyond standard physician visit documentation. The new tool is tailored to handle nursing-specific workflows, including timestamps, flowsheets, and shift handoffs.

Our read

Nursing documentation requires continuous updates and structured data entry that traditional physician-focused ambient scribes often fail to support. This release allows healthcare organizations to deploy ambient listening directly to nursing staff, addressing a major source of clinical burnout and shift overtime.

Proscia

Aug 6, 2026

HighVerified

Proscia received a new FDA 510(k) clearance for its Concentriq AP-Dx digital pathology platform. The clearance introduces a Predetermined Change Control Plan (PCCP), adds cloud deployment capabilities, and expands interoperability to include the Leica Aperio GT 450 DX slide scanner.

Our read

The inclusion of a PCCP allows laboratories to adopt future FDA-cleared scanners and displays without waiting for Proscia to submit additional 510(k) filings. The newly cleared cloud deployment option and expanded scanner compatibility also provide health systems with flexibility in how they implement and scale their digital pathology infrastructure.

HOPPR

Aug 6, 2026

MediumPartially Verified

HOPPR expanded its vision-language model portfolio with the release of a new 2D Mammography Narrative Model. The foundation model is designed to support AI development and narrative generation specifically for 2D mammography imaging.

Our read

This release allows healthcare organizations and developers to build and fine-tune AI applications for breast imaging. It expands the platform's clinical utility beyond chest X-rays and CT scans into women's health workflows.

Upheal

Aug 5, 2026

MediumVerified

Upheal introduced a pre-session preparation feature that surfaces relevant client context before scheduled appointments. The update is designed to help providers quickly review a client's status and history immediately prior to beginning a new session.

Our read

This capability reduces the administrative burden of chart review by automatically organizing past session data. Therapists can transition between clients more efficiently without manually digging through previous notes.

Autonomize AI

Aug 5, 2026

MediumVerified

Autonomize AI launched Autonomize Payment Integrity-FWA, an AI-powered healthcare claims review application available in the ServiceNow Store. Built natively on the ServiceNow Healthcare and Life Sciences data model, the application helps payers identify claims with potential fraud, waste, and abuse (FWA) risk. It accelerates clinical validation and automates Special Investigation Unit (SIU) workflows directly within the ServiceNow environment.

Our read

Healthcare payers utilizing ServiceNow can embed AI-driven FWA detection directly into their existing investigative workflows. This native integration eliminates the need to navigate fragmented data across multiple systems, streamlining the identification and review of high-risk claims.

Azra AI

Aug 5, 2026

MediumPartially Verified

Azra AI has integrated its care orchestration platform with Blackford's portfolio of over 130 medical imaging AI applications. This integration allows imaging findings detected by Blackford's algorithms to automatically trigger patient navigation and follow-up workflows within Azra AI.

Our read

Health systems utilizing Blackford for imaging AI can now directly connect diagnostic findings to care coordination. This ensures that incidental or critical findings are actively managed and routed to the appropriate care teams rather than lost in the system.

Circle Cardiovascular Imaging

Aug 5, 2026

HighVerified

Circle Cardiovascular Imaging released cvi42 v6.5, introducing automated phase offset correction, anti-aliasing, and pre-segmentation for 4D Flow. The update also adds editable plaque segmentation, expanded calcium scoring references, improved motion correction for quantitative perfusion, and a new Plaque Education Report.

Our read

These workflow automations reduce the manual preparation time required for 4D Flow and CT analysis, allowing clinicians to interpret studies faster. The addition of the Plaque Education Report and direct PDF printing also streamlines communication with referring physicians and patients.

Freed

Aug 5, 2026

LowVerified

Freed has released Knowledge Base 2.0 for its Front Desk AI receptionist product. The rebuilt experience makes it easier for practices to manage the information the AI agent uses to answer questions.

Our read

An updated knowledge base improves the accuracy of the AI receptionist. This reduces the need for human intervention and ensures patients receive correct practice information.

Freed

Aug 5, 2026

MediumVerified

Freed has launched a new Dictation feature for its AI Scribe product. The capability is now live for all customers on the Premier and Group pricing tiers.

Our read

This allows clinicians to dictate notes directly into the platform rather than relying solely on ambient listening. It provides more flexibility in how documentation is captured and edited.

Gleamer

Aug 5, 2026

HighPartially Verified

The FDA granted 510(k) clearance to Gleamer's BoneView AI software for pediatric fracture detection. This expands the tool's authorized use to include pediatric populations in clinical settings.

Our read

Expanding FDA clearance to pediatric patients allows health systems and imaging centers to utilize BoneView across a broader demographic, improving diagnostic confidence and standardizing trauma care for children.

Hyro

Aug 5, 2026

MediumVerified

Hyro has launched a new integration with ServiceNow to deliver voice and digital self-service capabilities for health systems. The integration connects Hyro's conversational AI agents with ServiceNow's workflow management to automate administrative tasks and patient interactions.

Our read

Healthcare organizations using ServiceNow can now directly connect Hyro's AI agents to their existing IT and administrative workflows. This reduces manual data entry for staff and streamlines patient self-service by automatically routing and resolving requests within the ServiceNow platform.

OpenEvidence

Aug 5, 2026

MediumVerified

OpenEvidence integrated Springer Nature's medical content into its platform, expanding the peer-reviewed literature available to ground its AI responses.

Our read

Clinicians using OpenEvidence will now receive answers synthesized from and cited to Springer Nature's extensive portfolio of medical journals and textbooks, improving the comprehensiveness of the platform's evidence base.

Insilico Medicine

Aug 4, 2026

MediumVerified

Insilico Medicine published a collaborative study in npj Precision Oncology demonstrating the use of its PandaOmics AI platform to identify therapeutic targets for inverted papilloma-associated sinonasal squamous cell carcinoma. The platform integrated transcriptomic data with pathway biology and protein interaction networks to map the molecular cascade of the disease.

Our read

This peer-reviewed publication provides concrete validation of the platform's ability to discover actionable targets in rare and poorly understood cancers. Buyers evaluating the software can use this evidence to assess its utility in complex multi-omic analysis and translational research.

Autonomize AI

Aug 4, 2026

HighVerified

Autonomize AI introduced Genie AI, an autonomous agent that functions as an intelligent healthcare workflow architect. The tool allows frontline healthcare teams to design and deploy production-ready workflows, such as utilization management and authorization reviews, using natural language prompts. It automatically assembles these workflows from approved enterprise capabilities, governed data sources, and validated AI agents within the Autonomize Intelligence Platform.

Our read

This capability lowers the technical barrier to entry for creating complex healthcare workflows, allowing clinical and operational experts to build automations without writing code. By restricting the agent to pre-approved data sources and validated components, organizations can accelerate AI adoption while maintaining enterprise IT governance and compliance.

Doctolib

Aug 4, 2026

HighPartially Verified

Doctolib launched a clinical AI research program in partnership with public institutes like Inria and Inserm to develop AI tools using patient medical histories. The initiative automatically includes user health data to train these AI models unless patients actively opt out via a provided form.

Our read

Healthcare organizations using Doctolib must be aware that patient data is being used by default to train the vendor's clinical AI models. This opt-out data governance approach may impact patient trust and requires providers to understand the privacy and compliance implications for their patient populations.

Hinge Health

Aug 4, 2026

HighVerified

Hinge Health has acquired Cylinder Health, a virtual-first digestive healthcare company, for $105 million. Through this acquisition, Hinge Health is expanding its platform to include an integrated Gastrointestinal Care Program, complementing its existing musculoskeletal and migraine offerings.

Our read

Healthcare buyers and benefits leaders can now consolidate their digital health point solutions by accessing musculoskeletal, migraine, and gastrointestinal care through a single vendor platform. This expansion addresses a major category of medical spend and provides a more unified experience for covered members.

TeraRecon

Aug 4, 2026

HighPartially Verified

TeraRecon released TeraRecon Neuro, a new software package designed to assist clinicians in diagnosing and treating neurovascular emergencies such as stroke. The application processes brain perfusion images from CT or MRI scanners to calculate perfusion parameters and generate 2D and 3D visualizations, including penumbra and umbra maps.

Our read

Radiology departments and stroke centers can deploy this dedicated neurovascular tool to accelerate clinical decision-making during time-critical emergencies. The automated generation of detailed parametric maps directly supports rapid triage and treatment planning for stroke patients.

Tempus

Aug 4, 2026

HighVerified

Tempus announced the publication of a study in Nature Medicine demonstrating the performance of PRISM2, its multimodal slide-level pathology foundation model developed with Microsoft. The model processes routine hematoxylin and eosin slides to predict biomarker status and patient prognosis without requiring specialized fine-tuning.

Our read

Clinical buyers and oncology researchers can leverage this peer-reviewed evidence to validate the diagnostic and prognostic accuracy of Tempus's pathology foundation models. The ability to extract deep biological insights from standard slides reduces the need for additional complex assays.

Primaa

Aug 4, 2026

MediumVerified

Primaa integrated its Cleo Skin AI solution with the PathPresenter Image Management System (IMS). The integration embeds Primaa's diagnostic assistance tools for melanoma, squamous cell carcinoma, and basal cell carcinoma directly into the PathPresenter digital pathology viewer.

Our read

Laboratories utilizing PathPresenter can now access Primaa's dermatopathology AI without leaving their primary image management workflow. This interoperability reduces friction in adopting AI tools and improves diagnostic turnaround times for common skin cancers.

Overjet

Aug 4, 2026

HighVerified

Overjet received FDA clearance for its IRIS Real-time Image Quality Checking system. The AI-powered tool flags eight image quality issues, such as cone cuts, overlapping contacts, and missed coverage, immediately after an X-ray is captured.

Our read

Dental practices can catch and correct imaging errors while the patient is still in the chair, reducing the need for later retakes and consolidating imaging software and diagnostic AI into a single system.

Guidehealth

Aug 3, 2026

HighVerified

Guidehealth became one of the first organizations to earn the new Health Care AI Accreditation from URAC. This independent certification validates the company's adherence to industry standards for responsible artificial intelligence governance, risk management, and trustworthiness.

Our read

Buyers can rely on this third-party accreditation as proof of the platform's commitment to safe AI deployment. It reduces the compliance evaluation burden by demonstrating that the vendor meets rigorous national standards for AI oversight.

Azra AI

Aug 3, 2026

MediumPartially Verified

Azra AI has partnered with RevealDx to integrate the mSI score for characterizing suspicious cancerous lung lesions into its oncology platform. The integration connects RevealDx's early lung cancer detection capabilities directly with Azra's care coordination and survivorship workflows.

Our read

Clinical teams can now automatically route patients identified with high-risk lung nodules by RevealDx into Azra AI's navigation pathways. This reduces the time to diagnosis and treatment for lung cancer patients by automating the triage process.

Counsel Health

Jul 31, 2026

HighPartially Verified

Counsel Health launched Counsel Studio, a white-label deployment platform enabling healthcare organizations to embed its AI-enabled virtual care interface directly into their own applications. The platform connects into existing digital portals via APIs, iFrames, or WebViews, allowing partners to customize the user interface and ingest their proprietary clinical protocols.

Our read

This release allows health plans and health systems to natively integrate AI triaging and physician-supervised care within their existing consumer applications. By embedding the service directly without requiring a separate app download, buyers can reduce friction and steer care in-network while maintaining full brand continuity.

Hinge Health

Jul 30, 2026

HighVerified

Hinge Health announced the publication of a non-randomized controlled trial in the Journal of Comparative Effectiveness Research evaluating its digital exercise therapy among adults aged 65 and older. The study demonstrated that participants at risk for falls who used the platform experienced 37 percent fewer falls and 57 percent lower odds of an emergency room visit over three months compared to a control group. Physical functioning and control also improved by 6.9 points more than the comparison group based on the SF-36 scale.

Our read

Healthcare buyers, particularly Medicare Advantage plans, can leverage this clinical validation to deploy the platform for senior populations to reduce avoidable utilization. The proven reduction in fall risk and emergency room visits directly translates to lower total medical spend and can positively impact quality Star Ratings.

Waiv

Jul 29, 2026

MediumVerified

Waiv released two robustified digital pathology foundation models, Phaet (based on Phikon-v2) and Mascaret (based on Midnight-12k), on Hugging Face for research use. The models were fine-tuned using a model-agnostic technique designed to remove their fragility to variations in slide scanners, laboratory procedures, and tissue staining.

Our read

Biopharma R&D teams and healthcare researchers can leverage these open-source foundation models to build computational pathology tools that generalize safely across multi-institutional datasets without silently losing accuracy due to site-specific technical artifacts.

PathAI

Jul 29, 2026

MediumPartially Verified

PathAI released version 2.21 of its AISight Dx digital pathology platform, introducing customizable case dashboards, an AI impressions widget, and expanded metadata support for bulk slide ingestion. The update adds support for Amazon S3 Glacier Deep Archive to move older digitized slides to cold storage, along with new slide review tools like editable linear measurements.

Our read

Administrators managing enterprise pathology workflows gain improved control over case prioritization and storage costs through the new dashboard and Amazon S3 Glacier archiving capabilities. The expanded metadata ingestion ensures that critical specimen and block identifiers from laboratory information systems are preserved when cases enter the digital viewer.

Ordr

Jul 29, 2026

MediumVerified

Ordr announced expanded ecosystem integrations across security, IT, and Zero Trust workflows, including a new integration with TruAsset. This update directly maps critical medical device security data, such as FDA recalls, CVEs, and network anomalies, into clinical engineering and asset management systems.

Our read

Clinical engineering teams can view real-time security context alongside maintenance records without switching platforms. This streamlined visibility helps healthcare organizations more efficiently prioritize and mitigate risks on critical equipment like infusion pumps and imaging systems.

Abridge

Jul 28, 2026

MediumVerified

Abridge acquired Altrina, an AI startup, to integrate its computer-use agent technology into the Abridge platform. This acquisition transitions the standalone Altrina platform into Abridge's infrastructure to automate multi-step workflows directly within electronic health records.

Our read

Buyers evaluating Abridge can expect the platform to expand beyond ambient clinical documentation into active workflow execution. By embedding Altrina's agents, Abridge aims to automate administrative tasks within the EHR, reducing manual clicks for clinicians.

Tali AI

Jul 27, 2026

MediumVerified

Tali AI announced a native integration with the Profile Electronic Health Record (EHR) by Intrahealth. Clinicians can now launch the AI scribe directly within the Profile interface, capture real-time encounter notes, and save them to the patient chart without switching tabs.

Our read

Organizations utilizing Profile by Intrahealth can embed AI scribing directly into their existing clinician workflows. This eliminates the friction of managing multiple windows and manually transferring data into the patient record.

Heartflow

Jul 27, 2026

MediumPartially Verified

Heartflow PCI Navigator entered commercial use outside of clinical trials, with The Valley Hospital becoming the first U.S. institution to deploy the software. The AI-powered tool provides interventional cardiologists with a personalized 3D model detailing vessel sizing, plaque buildup, and blood flow to plan coronary angioplasty and stent placement before entering the catheterization lab.

Our read

This marks the commercial availability of Heartflow's percutaneous coronary intervention planning capability, expanding the platform's utility from non-invasive diagnostics into interventional cardiology. Buyers can now evaluate this tool to gain pre-procedural insights, allowing clinical teams to establish treatment strategies and select device sizes before the procedure begins.

VUNO

Jul 24, 2026

MediumVerified

Researchers from VUNO published a peer-reviewed study in the American Journal of Neuroradiology validating a machine learning algorithm that uses automated brain MRI volumetry to differentiate frontotemporal dementia from Alzheimer's disease. The model, trained on 758 subjects and externally validated on 89 subjects, achieved 91.4 percent accuracy internally and significantly reduced interpretation time for experienced radiologists.

Our read

Clinical leaders and radiology buyers evaluating dementia triage solutions gain peer-reviewed validation of VUNO's MRI volumetry approach. The demonstrated time savings and diagnostic accuracy support the commercial deployment of such models in clinical workflows to separate overlapping neurodegenerative presentations.

Tali AI

Jul 24, 2026

HighVerified

Tali AI launched 'Call from Tali', a feature allowing clinicians to place outbound patient phone calls directly from the Tali platform. The system records both sides of the conversation and automatically generates structured, EHR-ready clinical notes from the audio.

Our read

Healthcare providers can capture and standardize documentation for telehealth and phone-based care without juggling separate calling applications. This reduces administrative overhead and ensures accurate context capture for remote patient interactions.

Tali AI

Jul 23, 2026

MediumVerified

Tali AI introduced the ability for clinicians to automatically generate and submit Ontario Health Insurance Plan (OHIP) claims directly through MC EDT within the Tali platform. The update also added one-click note exporting for custom templates into Med Access and introduced default templates specifically formatted for phone visits.

Our read

Clinics in Ontario can consolidate documentation and billing into a single workflow, saving time on claims submission. Users of Med Access EHR benefit from faster documentation transfer without manual copy-pasting.

Heidi Health

Jul 22, 2026

HighPartially Verified

Heidi Health released an impact report analyzing five real-world pilots across Ontario, Canada, involving 333 active clinicians and over 111,000 documented patient visits. The ambient AI scribe saved an average of 13 minutes per visit, while specific institutions such as the Ottawa Institute of CBT experienced a 66 percent reduction in documentation time.

Our read

Clinical and operational evidence from large-scale pilots provides healthcare buyers with validated return on investment and time-savings metrics. Real-world validation at named institutions helps organizations justify the implementation of ambient AI scribes for reducing clinician administrative burden.

Regard

Jul 21, 2026

HighPartially Verified

Regard published real-world outcome data from its deployment at Monument Health, demonstrating significant improvements in diagnostic capture. Over an eight-month period across two hospitals, the platform drove a 56% improvement in average Elixhauser scores, a 52% increase in HCC capture, and a 44% improvement in CC/MCC capture. At smaller facilities without prior clinical documentation improvement programs, the platform increased HCC capture by 352%.

Our read

Buyers require hard metrics to justify AI investments beyond qualitative time savings. These outcomes validate that Regard's chart review algorithms directly lift severity of illness scores, improve risk adjustment, and prevent revenue leakage without increasing the documentation burden on hospitalists.

Chai Discovery

Jul 12, 2026

HighPartially Verified

Chai Discovery deployed Chai-3, a next generation antibody design model that the company describes as roughly doubling the success rate of Chai-2 and binding more tightly to harder targets. Date recorded here is the date of the trade coverage confirming deployment; the company has not published a precise release date for Chai-3, and this record does not assert one.

Our read

For an R&D buyer the question is whether a model generation actually changes the design cycle or only the benchmark. The reported doubling is a vendor claim measured against the company's own prior model, not an independent comparison against competing methods, and no candidate designed by these models has published clinical results. What is verifiable is that named pharmaceutical organizations have licensed the platform into production R&D, including at least one custom model trained on a customer's proprietary data. That structure is the thing to scrutinize in procurement: a custom model trained on internal discovery data creates a different dependency, and different exit economics, than licensing a general model.

Nabla

Jul 6, 2026

MediumPartially Verified

Nabla appears to have withdrawn public per month pricing in favor of a demo and contract sales motion, particularly for organizations. The company historically published a free tier of roughly 30 consultations a month and a Pro plan reported near $119 per month. Third party listings now conflict on tier names and rates. Recorded as Partially Verified: the shift is consistently reported by third parties but was not confirmed in vendor published materials, and the date reflects the verification pass rather than an announcement.

Our read

This is a change in the buyer's favor being reversed, and it is worth noticing because the ambient scribe category is moving in two directions at once. Heidi restructured pricing upward in February 2026 but kept published tiers; Nabla appears to have withdrawn public pricing entirely. For a small practice or an individual clinician, that removes the ability to budget without a sales conversation and eliminates a self serve evaluation path that previously existed. For a health system it changes little, since enterprise contracts were always negotiated. The more consequential items to settle in that sales conversation are not the rate: confirm whether a Business Associate Agreement is included at your tier, and whether the default use of session data for model training can be contractually disabled.

HeartSciences

Jun 2, 2026

MediumVerified

HeartSciences released MyoVista Insights version 1.3 with an AI-ECG Algorithm Marketplace, making Bunkerhill Health's FDA cleared ECG-EF algorithm for detecting reduced left ventricular ejection fraction available through the platform. Both companies are indexed here, making this a distribution relationship between two vendors in this index: Bunkerhill developed and cleared the algorithm, HeartSciences distributes it.

Our read

This is a distribution event rather than a clearance, and the distinction matters. The cleared algorithm belongs to Bunkerhill; HeartSciences supplies the platform that delivers it. For a community hospital, critical access hospital, or primary care practice, that is the substantive change: a cleared AI-ECG model detecting reduced ejection fraction becomes reachable without a direct enterprise agreement with the algorithm developer, in a setting where echocardiography is often not readily available. Buyers evaluating MyoVista Insights should be clear that the AI they gain access to today is Bunkerhill's, since HeartSciences' own algorithms for impaired cardiac relaxation and low ejection fraction remain in development and unsubmitted or in pre submission. Assistive AI-ECG assessments are reimbursable under the Hospital Outpatient Prospective Payment System at APC 5734.

Subtle Medical

May 27, 2026

MediumVerified

Subtle Medical received FDA clearance for SubtleHD (PET), a next generation AI PET image enhancement product for PET/CT and PET/MR systems. The company states it supports all FDA approved radiotracers, enables up to 75 percent faster PET imaging on existing scanners, improves SUVmax quantitation accuracy, allows radiologist adjustable denoising levels, and incorporates anatomical CT data into reconstruction. It extends prior clearances covering SubtlePET and SubtleHD (MR).

Our read

PET scanner capacity is a hard constraint for most imaging programs, and acquisition acceleration is one of the few levers that adds throughput without capital equipment. The material detail for buyers is radiotracer compatibility: support across all FDA approved radiotracers, rather than 18F-FDG alone, is what makes this usable in theranostics and advanced molecular imaging programs where the older generation was limited. Two caveats worth carrying into procurement: the acceleration figure is a vendor claim and should be validated against your own protocols and reader acceptance, and adjustable denoising means image appearance becomes a configurable parameter, which needs a documented standard rather than per radiologist preference drift.

Bunkerhill Health

Apr 15, 2026

HighVerified

CMS established a national billing code and associated payment under the Hospital Outpatient Prospective Payment System for algorithmic analysis of coronary artery calcium and aortic valve calcium on chest CT, effective April 1, 2026. The company separately received FDA clearance for Bunkerhill Contrast CAC and Bunkerhill Contrast AVC, which it states are the first AI algorithms cleared to detect and quantify coronary artery calcium and aortic valve calcium on contrast enhanced, routine non gated chest CT, extending prior clearances that covered non contrast chest CT.

Our read

Two things changed here and the second matters more. FDA clearance on contrast enhanced non gated chest CT means the algorithm can run opportunistically on scans a health system is already acquiring for other reasons, rather than requiring a dedicated gated cardiac study. That converts an existing imaging volume into a screening surface without new acquisition cost. The CMS billing code is the rarer event: most healthcare AI carries no reimbursement pathway at all and must be justified purely on internal ROI, so a national OPPS payment moves this from a cost center argument to a billable service line. Buyers evaluating this platform should separate the two economic questions, since the reimbursement applies to specific algorithmic analysis and not to the cost of licensing the platform itself.

Caris Life Sciences

Mar 26, 2026

MediumVerified

Caris added two Caris AI Insights signatures assessing brain metastasis risk in breast and lung cancer, bringing its proprietary signature count to seven. The signatures were trained on 12,994 NSCLC cases and 3,371 breast cancer cases with matched survival outcomes, and generate a personalized predictive score from a patient's whole exome and whole transcriptome data, visualized as Kaplan Meier curves. They are delivered in the Caris Molecular Tumor Board Report, a research use only report available at no additional cost when ordering MI Cancer Seek.

Our read

The signature itself matters less than what it reveals about how to read this vendor. Caris publishes training cohort sizes per signature, which is more disclosure than most AI diagnostics offer and lets a clinician judge whether their patient population is represented. But the signatures ship inside a research use only report, while the underlying MI Cancer Seek assay carries FDA approved companion diagnostic indications. Those are different regulatory objects arriving in the same envelope at no extra cost, and the distinction governs how a result can be used in a treatment decision. Confirm with your pathology and legal teams which outputs are approved for clinical use before signatures reach a tumor board.

Elation Health

Mar 6, 2026

MediumPartially Verified

Elation Health launched AI Fast Lane, applying Smart Coding to primary care billing. The system reads pre visit details, the patient problem list, active medications, and the visit note (often drafted by its Note Assist ambient scribe) and suggests diagnosis, procedure, and drug codes, shifting the biller's task from building a claim to confirming a suggestion. Claims that meet a defined confidence threshold bypass the manual review queue and are submitted automatically.

Our read

For an independent practice already on Elation, this is the case for consolidating rather than buying a separate coding tool, and the AI carries no additional line item. The provision that deserves scrutiny in procurement is the touchless lane itself. Claims above a confidence threshold submit without human review, which is where the efficiency comes from and also where the compliance exposure sits. Ask who sets the threshold, whether it is auditable, what the error rate is on auto submitted claims, and who is accountable for a miscoded claim that was never seen by a person. Bundled AI at no extra cost is a genuine economic advantage over a specialist tool, but only where the practice was going to run this EHR regardless.

Heidi Health

Feb 1, 2026

HighPartially Verified

Heidi restructured its pricing in February 2026 and moved upmarket. The main paid tier, previously reported near $90 a month, became Clinician at $150 per user per month billed annually, with an Evidence Plus tier reported near $40, a Practice tier adding EHR integrations, and quote based Enterprise plans with SSO and custom hosting. The free tier remains, with unlimited transcription and 10 Pro Actions a month. Sources conflict on some tier amounts.

Our read

This is the single most consequential change for anyone already using or evaluating Heidi. The free and individual tiers remain genuinely usable for trialling the product on real clinic days, which is rare in this category. But two gates moved upmarket: push to chart EHR integration and an organization wide Business Associate Agreement are both reported as available only from the Practice tier upward. For a US organization, that means the entry tiers are not a viable production configuration for PHI handling regardless of how well the scribe performs, and the evaluation should be run against the tier you would actually buy.

Aidoc

Jan 21, 2026

HighVerified

The FDA cleared Aidoc's comprehensive abdomen CT triage solution, powered by its self developed CARE foundation model, bringing 11 newly cleared indications together with three previously cleared into a single 14 indication workflow. The company states this is the first FDA clearance of a double digit set of acute indications powered by one foundation model. In the FDA reviewed pivotal study the new indications reported a mean sensitivity of 97 percent and mean specificity of 98 percent, and the company reports roughly an order of magnitude reduction in false alerts compared with leading single condition tools.

Our read

The operationally decisive number here is not the sensitivity, it is the false alert rate. Triage AI fails in practice when radiologists learn to ignore it, and single condition tools deployed side by side compound that problem because each one alerts independently. A reported order of magnitude reduction in false alerts, if it holds in a buyer's own case mix, is what determines whether the tool survives past month three. Two things to establish in evaluation: that the cleared indications match the acute findings actually driving delays in your emergency department, and how the platform governs models it did not build, since aiOS also hosts third party AI and the governance layer is doing work across all of them.

Pearl

Dec 18, 2025

MediumVerified

Pearl received FDA clearance extending Second Opinion to panoramic radiographs, covering detection of suspected caries, periapical radiolucencies, and impacted third molars. The clearance was supported by a standalone performance study and a fully crossed multi reader, multi case study, with the company reporting stable performance across gender, geography, and imaging device subgroups. With this clearance the platform spans bitewing, periapical, panoramic, and CBCT imaging.

Our read

The clinically interesting part is the study design, not the clearance itself. A fully crossed multi reader, multi case study is the appropriate design for a reader assistance claim, because it measures whether clinicians perform better with the tool rather than whether the model performs well alone, and relatively few AI vendors in any specialty run one. The reported stability of performance across gender, geography, and imaging device subgroups is also a genuine fairness disclosure, which remains the emptiest axis across this index. Buyers should still confirm that the imaging devices in their own practice are represented in the validation population.

ArteraAI

Dec 18, 2025

HighVerified

The ArteraAI Prostate Test was included in the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer, making it the first AI enabled risk stratification tool recommended in those guidelines. It carries a Level 1B evidence rating under Simon Criteria and a Category 2A recommendation. This followed FDA De Novo marketing authorization in August 2025 and CMS coverage effective January 2024.

Our read

Guideline inclusion is a different class of validation from a vendor claim or even a regulatory clearance, because an independent panel evaluates the underlying evidence and decides whether clinicians should consider the tool at all. For a center weighing AI diagnostics, this is the clearest available answer to the question of whether a test has been assessed by people with no commercial interest in the answer. The specific standing matters: Level 1B evidence under Simon Criteria and a Category 2A recommendation indicating uniform NCCN consensus that the test is a useful option. Note also what the guideline language constrains, since it positions the test as used in addition to NCCN risk category, patient characteristics, and patient preference, which is an externally imposed limit on how far the output may be relied upon.

Cohere Health

Sep 1, 2025

MediumPartially Verified

Cohere Health acquired ZignaAI in September 2025 and launched the Cohere Payment Integrity Suite, extending its clinical AI from pre service prior authorization into post service claims and coding validation. The company subsequently launched specialized audit agents for high cost conditions including sepsis, reporting a 58 percent findings rate, and states the combined pre and post service view achieves up to 9x return on investment.

Our read

Two things matter here beyond the acquisition itself. First, scope creep across the claim lifecycle: a platform that decides authorization before care and then audits payment after care sits on both sides of the same clinical event, which is efficient for the plan and worth examining for providers, since the evidence surfaced at authorization is explicitly reused to validate the claim. Second, the audit agents carry a stated 58 percent findings rate on conditions like sepsis. A findings rate is a measure of how often the model flags something, not how often it is right, and sepsis coding is among the most contested areas in payment integrity. Plans should establish the confirmation rate on appeal, not just the findings rate, before treating that number as savings.

Tempus

Mar 1, 2025

MediumVerified

Tempus acquired Deep 6 AI in March 2025, adding an AI precision research platform that mines structured and unstructured EMR data to match patients to clinical trials and generate real world evidence. Deep 6 continues to operate under its own name and reports real time EMR feeds across more than 30 health systems and an ecosystem of over 1,000 research facilities. This index records the capability inside the Tempus vendor entry rather than as a separate record, consistent with how other acquired product lines are handled.

Our read

For a health system already running Tempus Next or Hub, this quietly widens what the relationship covers: the same vendor now sits on clinical decision support, prior authorization, and trial recruitment, all reading the same EMR. That consolidation is convenient and worth scrutinizing, since the data access granted for one purpose now serves several. The technically interesting claim is about unstructured data: Deep 6 reports that 92 percent of trial inclusion and exclusion criteria benefit from unstructured sources and that 15 to 20 percent of eligible patients are found through free text alone, which is the actual argument for NLP based matching over coded data queries. Two things to establish: that data ownership remains with the health system rather than transferring with the platform, and that matched cohorts are treated as decision support requiring validation, which the company itself states.